DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qh4kdv/anyara_renal) has announced the addition of the "Anyara (Renal Cell Carcinoma) - Analysis and Forecasts to 2022" report to their offering.
Anyara (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 provides Afinitor sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2022). The report also includes information on Renal Cell Carcinoma market.
Scope
- Therapy area profile including patient population for the EU5
- Analysis and review of Anyara including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Anyara including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2012-2022 for Anyara in the EU5 markets
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in EU5 markets
- Obtain sales forecast for currently marketed/pipeline drug for 2012-2022 for all seven major markets
For more information visit http://www.researchandmarkets.com/research/qh4kdv/anyara_renal